Anti program death-1/anti program death-ligand 1 in digestive cancers

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Human tumors evade immune surveillance by activating immune checkpoints like PD-1/PD-L1.
• PD-L1 upregulation on cancer cells contributes to T cell anergy.
• Immune checkpoint inhibitors (ICIs) are designed to restore anti-tumor T cell activity.

Purpose of the Study:

• To review the current landscape of PD-1 and PD-L1 blockade in digestive cancers.
• To highlight ongoing clinical trials and preliminary results.
• To identify key challenges and future directions for ICI therapy in this patient population.

Main Methods:

• Review of accumulating clinical data and ongoing trials.
• Analysis of PD-L1 expression as a predictive biomarker.
• Discussion of therapeutic sequencing and combination strategies.

Main Results:

• PD-L1 expression is found in 30-50% of digestive cancers.
• Multiple anti-PD-1 and anti-PD-L1 agents are under investigation.
• Promising preliminary results exist for gastric and colorectal cancers, with ongoing trials.

Conclusions:

• ICIs represent a promising therapeutic avenue for digestive cancers.
• Challenges include determining optimal patient selection, treatment timing, and combinations.
• Biomarker development is crucial for personalized ICI therapy.